NO20005005D0 - Nye krystallinske former av en antiviral benzimidazolforbindelse - Google Patents

Nye krystallinske former av en antiviral benzimidazolforbindelse

Info

Publication number
NO20005005D0
NO20005005D0 NO20005005A NO20005005A NO20005005D0 NO 20005005 D0 NO20005005 D0 NO 20005005D0 NO 20005005 A NO20005005 A NO 20005005A NO 20005005 A NO20005005 A NO 20005005A NO 20005005 D0 NO20005005 D0 NO 20005005D0
Authority
NO
Norway
Prior art keywords
crystalline forms
new crystalline
benzimidazole compound
antiviral
antiviral benzimidazole
Prior art date
Application number
NO20005005A
Other languages
English (en)
Other versions
NO20005005L (no
Inventor
Barry Howard Carter
Bobby Neal Glover
Lian-Feng Huang
Stacey Todd Long
Michele Catherine Rizzolio
Barry Riddle Sickles
Robert William Lancaster
Eric Allen Schmitt
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20005005D0 publication Critical patent/NO20005005D0/no
Publication of NO20005005L publication Critical patent/NO20005005L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052Imidazole radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO20005005A 1998-04-07 2000-10-04 Nye krystallinske former av en antiviral benzimidazolforbindelse NO20005005L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807354.7A GB9807354D0 (en) 1998-04-07 1998-04-07 Antiviral compound
PCT/EP1999/002214 WO1999051618A1 (en) 1998-04-07 1999-04-01 Novel crystalline forms of an antiviral benzimidazole compound

Publications (2)

Publication Number Publication Date
NO20005005D0 true NO20005005D0 (no) 2000-10-04
NO20005005L NO20005005L (no) 2000-12-06

Family

ID=10829932

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005005A NO20005005L (no) 1998-04-07 2000-10-04 Nye krystallinske former av en antiviral benzimidazolforbindelse

Country Status (28)

Country Link
US (9) US6469160B1 (no)
EP (1) EP1071693B1 (no)
JP (1) JP2002510703A (no)
KR (1) KR20010074472A (no)
CN (1) CN1303390A (no)
AP (1) AP2000001947A0 (no)
AT (1) ATE261452T1 (no)
AU (1) AU752877B2 (no)
BR (1) BR9909474A (no)
CA (1) CA2327494C (no)
DE (1) DE69915461T2 (no)
EA (1) EA002970B1 (no)
EE (1) EE04120B1 (no)
ES (1) ES2216503T3 (no)
GB (1) GB9807354D0 (no)
HR (1) HRP20000669A2 (no)
HU (1) HUP0101669A3 (no)
ID (1) ID27109A (no)
IL (1) IL138697A0 (no)
IS (1) IS5640A (no)
NO (1) NO20005005L (no)
NZ (1) NZ507173A (no)
PL (1) PL343397A1 (no)
SK (1) SK14832000A3 (no)
TR (1) TR200002860T2 (no)
WO (1) WO1999051618A1 (no)
YU (1) YU60900A (no)
ZA (1) ZA200005153B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
GB9807355D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
GB0008939D0 (en) * 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
EA007120B8 (ru) 2002-05-16 2012-03-30 Тиботек Фармасьютикалз Лтд. Псевдополиморфные формы ингибитора вич-протеазы
CN1960992B (zh) * 2004-06-02 2011-10-19 桑多斯股份公司 晶体形式的美罗培南中间体
EP1910393A2 (en) * 2005-07-05 2008-04-16 Hetero Drugs Limited A novel process for the preparation of didanosine using novel intermediates
US9198862B2 (en) * 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
EA018698B1 (ru) * 2005-09-21 2013-10-30 4Сц Аг Сульфонилпирролгидрохлориды как ингибиторы гистондезацетилазы
BRPI0617947A2 (pt) * 2005-10-31 2011-08-09 Janssen Pharmaceutica Nv processos para a preparação de derivados de piperazinil e diazapanil benzamida
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
EP2076516B1 (en) * 2006-10-27 2013-12-11 Signal Pharmaceuticals LLC Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
KR101043794B1 (ko) * 2009-04-13 2011-06-27 청우산업 주식회사 황토판재로 제공되는 기능성 황토방
CA2792844C (en) 2010-03-12 2014-12-09 Omeros Corporation Pde10 inhibitors and related compositions and methods
CA2808904A1 (en) * 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
US8546344B2 (en) 2010-10-28 2013-10-01 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl)-1H-benzimidazole
US8940707B2 (en) 2010-10-28 2015-01-27 Viropharma Incorporated Maribavir isomers, compositions, methods of making and methods of using
US8541391B2 (en) 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
JP2014530805A (ja) * 2011-09-30 2014-11-20 スンシネ ルアケ プハルマ カンパニー リミテッド アジルサルタンの結晶形並びにその製造及び使用
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途
WO2024081308A1 (en) * 2022-10-12 2024-04-18 Takeda Pharmaceutical Company Limited Method of preparing maribavir

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399987A (en) * 1965-08-02 1968-09-03 United States Borax Chem 2-alkylaminobenzimidazoles as herbicides
CH443777A (de) * 1965-08-06 1968-02-15 Agripat Sa Verfahren zum Schützen textiler Keratinfasern vor Insektenfrass und Mittel zur Durchführung dieses Verfahrens
US3655901A (en) * 1970-07-30 1972-04-11 Merck & Co Inc Method of inhibiting the formation of phenylethanalamine-n-methyl transferase with 2-aminobenzimidazoles
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
US5248672A (en) * 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
AU5447094A (en) * 1992-10-21 1994-05-09 Regents Of The University Of Michigan, The Polysubstituted benzimidazoles as antiviral agents
GB9413724D0 (en) 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
GB9600143D0 (en) 1996-01-05 1996-03-06 Wellcome Found Therapeutic compounds
GB9807355D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound

Also Published As

Publication number Publication date
US9163052B2 (en) 2015-10-20
US7297683B2 (en) 2007-11-20
EP1071693A1 (en) 2001-01-31
US20080103186A1 (en) 2008-05-01
IS5640A (is) 2000-09-26
US20170002035A1 (en) 2017-01-05
US20100179101A1 (en) 2010-07-15
YU60900A (sh) 2003-07-07
AU752877B2 (en) 2002-10-03
EE04120B1 (et) 2003-08-15
CA2327494A1 (en) 1999-10-14
IL138697A0 (en) 2001-10-31
US20160030460A1 (en) 2016-02-04
JP2002510703A (ja) 2002-04-09
US20180044366A1 (en) 2018-02-15
BR9909474A (pt) 2000-12-19
WO1999051618A1 (en) 1999-10-14
TR200002860T2 (tr) 2000-12-21
NZ507173A (en) 2003-07-25
US6469160B1 (en) 2002-10-22
US20020177703A1 (en) 2002-11-28
SK14832000A3 (sk) 2001-07-10
DE69915461D1 (de) 2004-04-15
EP1071693B1 (en) 2004-03-10
EA200000911A1 (ru) 2001-04-23
ZA200005153B (en) 2001-09-26
EE200000584A (et) 2002-04-15
ID27109A (id) 2001-03-01
PL343397A1 (en) 2001-08-13
DE69915461T2 (de) 2005-03-03
AU3603499A (en) 1999-10-25
CN1303390A (zh) 2001-07-11
GB9807354D0 (en) 1998-06-03
ATE261452T1 (de) 2004-03-15
HUP0101669A2 (hu) 2001-10-28
US20110118203A1 (en) 2011-05-19
HUP0101669A3 (en) 2003-07-28
AP2000001947A0 (en) 2000-12-31
ES2216503T3 (es) 2004-10-16
HRP20000669A2 (en) 2001-08-31
NO20005005L (no) 2000-12-06
US7714123B2 (en) 2010-05-11
EA002970B1 (ru) 2002-12-26
CA2327494C (en) 2010-10-26
KR20010074472A (ko) 2001-08-04
US20130261294A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
NO20005005L (no) Nye krystallinske former av en antiviral benzimidazolforbindelse
NO20000226D0 (no) Nye spiroazabicykliske heterocykliske forbindelser
NO996572D0 (no) Nye substituerte imidazolforbindelser
NO20011083L (no) Krystallinske former av EtOC2--CH2-(R)Cgl-Aze-Pab-OH
PT1070058E (pt) Hidroxiamidas de acido (4-aril-sulfonilamino)-tetra-hidropirano-4-carboxilico
NO983181L (no) Nye substituerte imidazolforbindelser
NO20010899L (no) Forbedring av ugunstige apomorfin-effekter
NO974605L (no) Nye heterosykliske forbindelser
DK1237857T3 (da) Nye Phenalkyloxyphenylderivater
NO20020030L (no) Krystallinske 1-metylkarbapenemforbindelser
FI19992855A (fi) Valaisuolosuhteiden mittaus
NO20023072L (no) Syntese av krystallinske silikoaluminofosfater
NO20002696D0 (no) Nye forbindelser med cGMP-PDE-inhibitoreffekt
PT1246817E (pt) Derivados de 4-fenil-1-piperazinilo, -piperidinilo e -tetra-hidropiridilo
NO20011790D0 (no) Nye imidazoler med anti-inflammatorisk aktivitet
NO20011804L (no) En forbedret fremgangsmåte for fremstilling av nye antidiabetiske midler
DK1196431T3 (da) En i det væsentlige krystallinsk form af melagatran
NO20010553D0 (no) Krystallinske former av osanetant
NO994027D0 (no) Polymorf av zopolrestat-monohydrat
NO20002012L (no) Nye polymorfe former av cipamfylline
EE200100017A (et) N-tert-butüülhüdroksüülamiini uued soolad
PT1175417E (pt) Compostos substituidos de benzolactamas
NO981216L (no) Nye heterosykliske forbindelser
NO20004583D0 (no) Krystallinsk form av paroxetine
NO995430D0 (no) Nye heterosykliske forbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application